BPI
Bactericidal permeability-increasing protein
Also known as: BPI_HUMAN, BPIFD1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P17213
- Gene
- BPI
- Ensembl
- ENSG00000101425
- Chromosome
- 20
- Canonical length
- 487 aa
- Protein class
- Predicted intracellular proteins, Predicted secreted proteins, Transporters
- Secretome location
- Secreted to blood
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene encodes a lipopolysaccharide binding protein. It is associated with human neutrophil granules and has antimicrobial activity against gram-negative organisms. [provided by RefSeq, Nov 2014]
Canonical amino-acid sequenceUniProt
487 residues, UniProt reviewed canonical sequence.
>P17213|BPI
1 MRENMARGPC NAPRWASLMV LVAIGTAVTA AVNPGVVVRI SQKGLDYASQ QGTAALQKEL
61 KRIKIPDYSD SFKIKHLGKG HYSFYSMDIR EFQLPSSQIS MVPNVGLKFS ISNANIKISG
121 KWKAQKRFLK MSGNFDLSIE GMSISADLKL GSNPTSGKPT ITCSSCSSHI NSVHVHISKS
181 KVGWLIQLFH KKIESALRNK MNSQVCEKVT NSVSSELQPY FQTLPVMTKI DSVAGINYGL
241 VAPPATTAET LDVQMKGEFY SENHHNPPPF APPVMEFPAA HDRMVYLGLS DYFFNTAGLV
301 YQEAGVLKMT LRDDMIPKES KFRLTTKFFG TFLPEVAKKF PNMKIQIHVS ASTPPHLSVQ
361 PTGLTFYPAV DVQAFAVLPN SSLASLFLIG MHTTGSMEVS AESNRLVGEL KLDRLLLELK
421 HSNIGPFPVE LLQDIMNYIV PILVLPRVNE KLQKGFPLPT PARVQLYNVV LQPHQNFLLF
481 GADVVYKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against BPI can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.29
- Highest tissue expression
- 1,420 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 1,420 nTPM
- testis: 16 nTPM
- spleen: 12 nTPM
- lung: 3.7 nTPM
- thymus: 3.5 nTPM
- kidney: 3.2 nTPM
Single-cell type
- neutrophil progenitors: 849 nCPM
- late spermatids: 294 nCPM
- early spermatids: 251 nCPM
- late primary spermatocytes: 97 nCPM
- neutrophils: 59 nCPM
- tuft cells: 12 nCPM
Immune cell
- classical monocyte: 15 nTPM
- total PBMC: 9.8 nTPM
- neutrophil: 7.1 nTPM
- myeloid DC: 0.6 nTPM
- non-classical monocyte: 0.6 nTPM
- intermediate monocyte: 0.2 nTPM
Brain region
- cerebral cortex: 0.4 nTPM
- choroid plexus: 0.4 nTPM
- basal ganglia: 0.3 nTPM
- midbrain: 0.3 nTPM
- hippocampal formation: 0.2 nTPM
- hypothalamus: 0.2 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about BPI.
Disease | AutoantibodyPubMed
Conditions in which antibodies against BPI are reported. Each links to that disease's full target list.
Showing 4 of 7 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for BPI from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
55 publications
- Bactericidal/permeability-increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis.
1995 · Clin Exp Immunol · RCR 5.1 · 153 citations - Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis.
1996 · QJM · RCR 3.3 · 101 citations - The role for neutrophil extracellular traps in cystic fibrosis autoimmunity.
2016 · JCI Insight · RCR 2.4 · 64 citations - The bactericidal/permeability-increasing protein (BPI) in infection and inflammatory disease.
2007 · Clin Chim Acta · RCR 2.4 · 94 citations - Antimicrobial peptides and colitis.
2013 · Curr Pharm Des · RCR 2.3 · 73 citations
Show 20 more of 55 total
- Clinical and immunological study of 7 patients with minocycline-induced autoimmune phenomena.
1998 · Am J Med · RCR 2.3 · 63 citations - Antineutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease.
1997 · Gut · RCR 2.2 · 69 citations - Killing three birds with one BPI: Bactericidal, opsonic, and anti-inflammatory functions.
2021 · J Transl Autoimmun · RCR 2.1 · 26 citations - Anti-neutrophil cytoplasmic antibodies (ANCA) against bactericidal/permeability-increasing protein (BPI) and cystic fibrosis lung disease.
1999 · Clin Exp Immunol · RCR 1.4 · 54 citations - From infection to autoimmunity: a new model for induction of ANCA against the bactericidal/permeability increasing protein (BPI).
2007 · Autoimmun Rev · RCR 1.4 · 46 citations - Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: defined specificities may be associated with distinct clinical features.
1998 · Am J Med · RCR 1.3 · 44 citations - Antineutrophil cytoplasmic autoantibodies (ANCA) in children with cystic fibrosis.
1998 · J Autoimmun · RCR 1.2 · 36 citations - Pseudomonas aeruginosa in cystic fibrosis: pyocyanin negative strains are associated with BPI-ANCA and progressive lung disease.
2011 · J Cyst Fibros · RCR 1.1 · 31 citations - Autoantibody response to BPI predict disease severity and outcome in cystic fibrosis.
2007 · J Cyst Fibros · RCR 1.1 · 38 citations - Frequency of anti-bactericidal/permeability-increasing protein (BPI) and anti-azurocidin in patients with renal disease.
1996 · Clin Exp Immunol · RCR 1 · 26 citations - The target antigens of antineutrophil cytoplasmic antibodies (ANCA) induced by propylthiouracil.
2007 · Int Immunopharmacol · RCR 0.9 · 28 citations - Dissociation of systemic and mucosal autoimmunity in cystic fibrosis.
2020 · J Cyst Fibros · RCR 0.9 · 16 citations - Anti-neutrophil cytoplasmic antibodies in patients with chronic liver diseases: prevalence, antigen specificity and predictive value for diagnosis of autoimmune liver disease. Swedish Internal Medicine Liver Club (SILK).
2000 · J Gastroenterol Hepatol · RCR 0.8 · 31 citations - Pseudomonas-induced lung damage in cystic fibrosis correlates to bactericidal-permeability increasing protein (BPI)-autoantibodies.
2003 · Clin Exp Rheumatol · RCR 0.8 · 26 citations - Autoantibodies against the bactericidal/permeability-increasing protein from inflammatory bowel disease patients can impair the antibiotic activity of bactericidal/permeability-increasing protein.
2004 · Inflamm Bowel Dis · RCR 0.7 · 32 citations - Clinical associations and characterisation of antineutrophil cytoplasmic antibodies directed against bactericidal/permeability-increasing protein and azurocidin.
2000 · Rheumatol Int · RCR 0.7 · 22 citations - Bactericidal/permeability-increasing protein and cathepsin G are the major antigenic targets of antineutrophil cytoplasmic autoantibodies in systemic sclerosis.
2003 · J Rheumatol · RCR 0.7 · 28 citations - Anti-neutrophil cytoplasmic antibodies directed against the bactericidal/permeability-increasing protein (BPI) in pediatric cystic fibrosis patients do not recognize N-terminal regions important for the anti-microbial and lipopolysaccharide-binding activity of BPI.
2000 · Pediatr Allergy Immunol · RCR 0.7 · 26 citations - Antineutrophil cytoplasmic antibodies directed against bactericidal/permeability-increasing protein detected in children with cystic fibrosis inhibit neutrophil-mediated killing of Pseudomonas aeruginosa.
2003 · Microbes Infect · RCR 0.7 · 29 citations - Anti-neutrophil cytoplasmatic antibodies and lung disease in cystic fibrosis.
2004 · J Cyst Fibros · RCR 0.7 · 25 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.25
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.78
- DepMap mean gene effect
- 0.03
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- defense response to Gram-negative bacterium
- innate immune response
- lipopolysaccharide-mediated signaling pathway
- negative regulation of interleukin-6 production
- negative regulation of interleukin-8 production
- negative regulation of macrophage activation
- negative regulation of tumor necrosis factor production
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Lipid-binding serum glycoprotein, C-terminal
- Lipid-binding serum glycoprotein, N-terminal
- Bactericidal permeability-increasing protein, alpha/beta domain superfamily
- Lipid-binding serum glycoprotein, conserved site
- Lipid binding protein BPI/LBP
- BPI/LBP/Plunc family
- LBP / BPI / CETP family, N-terminal domain
- LBP / BPI / CETP family, C-terminal domain
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads BPI as an antibody target. Whether an autoantibody or antibody against BPI could matter depends on whether native BPI is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
BPI is annotated as secreted, so native BPI circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label BPI as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...